This is the single most important concern with any telomerase-activating intervention, and it deserves a thorough answer.

You're correct that ~85-90% of human cancers upregulate telomerase (via hTERT expression) to maintain telomere length and achieve replicative immortality. So the question "could exogenous telomerase activation promote cancer?" is entirely legitimate.

The counterarguments:

1. Telomerase activation alone is not sufficient for malignant transformation. Cancer requires multiple hallmark capabilities (evasion of growth suppressors, sustained proliferative signaling, resistance to apoptosis, etc.). Telomere maintenance is just one piece of a complex puzzle.
2. Short telomeres may actually increase cancer risk. Critically short telomeres cause genomic instability (chromosome fusions, breakage-fusion-bridge cycles) which can initiate carcinogenesis. There's epidemiological evidence that shorter telomeres are associated with higher cancer incidence in some studies.
3. Khavinson's animal studies reported no increase in tumor incidence. In fact, the Anisimov et al. (2003) study in mice showed a non-significant trend toward reduced tumor incidence in the treated group.

However, I want to be intellectually honest: the absence of evidence is not evidence of absence. Long-term safety data on telomerase-activating compounds in humans simply doesn't exist. If you have a personal or family history of cancer, extra caution is warranted.

What about TA-65 (cycloastragenol), the other telomerase activator? Anyone compared it to Epithalon?

TA-65 is a small molecule (not a peptide) derived from Astragalus membranaceus. It has more published human data than Epithalon — Harley et al. (2011, PMID: 21426483) published a study showing modest telomerase activation in human subjects. But the effect size was small, the study had limitations, and TA-65 is significantly more expensive ($200-600/month depending on dose).

Comparison:

• TA-65: More human data, oral administration (convenient), but expensive and modest effects
• Epithalon: Less human data, injectable (less convenient), cheaper per cycle, potentially stronger telomerase activation in cell studies

Neither has robust enough evidence to make a strong recommendation. If longevity is your goal, the evidence base for exercise, caloric restriction, sleep optimization, and metabolic health (which semaglutide addresses) is orders of magnitude stronger than anything in the telomerase activation space.

Excellent balanced discussion. This is how we should approach longevity peptides — acknowledging both the research that exists and its significant limitations. The take-home: Epithalon is an interesting research compound with preliminary data, not a proven anti-aging intervention. Manage expectations accordingly.

And as always — focus on the fundamentals first. No peptide will compensate for poor sleep, sedentary lifestyle, or metabolic dysfunction. 🔬